Boston Scientific Corp (BSX) 18.41 $BSX
Boston Scientific Has Returned 42.5% Since SmarTrend Recommendation (BSX)
Comtex SmarTrend(R) - Wed Apr 22, 9:18AM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on October 24th, 2014 at $12.89. In approximately 6 months, Boston Scientific has returned 42.49% as of today's recent price of $18.36.
BSX: 18.41 (+0.10)
Boston Scientific (BSX) Breaks Through Resistance at $18.38
Comtex SmarTrend(R) - Wed Apr 22, 9:10AM CDT
Shares of Boston Scientific (NYSE:BSX) have bullishly opened above the pivot of $18.25 today and have reached the first resistance level of $18.38. Analysts will be watching for a cross of the next upside pivot targets of $18.44 and $18.63.
BSX: 18.41 (+0.10)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), UPI: 1.22 (-0.03), CYBX: 63.59 (+0.27)
C. R. Bard (BCR) Q1 Earnings: Lutonix DCB Holds the Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:20PM CDT
C.R. Bard Inc. (BAX) is set to report first-quarter 2015 earnings results on Apr 23.
BSX: 18.41 (+0.10), BIIB: 423.57 (+1.46), BCR: 175.09 (+0.24), ATHN: 120.16 (-1.35)
Long-Term Data Underscore Safety And Efficacy Of The Boston Scientific S-ICD(TM) System
PR Newswire - Mon Apr 20, 3:01PM CDT
Today the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX) S-ICD System(TM) (subcutaneous implantable defibrillator) for patients at risk of sudden cardiac arrest.
BSX: 18.41 (+0.10)
MedIntelliBase Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks"
M2 - Mon Apr 20, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fgkmfx/medintellibase) has announced the addition of the "MedIntelliBase? Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks" " subscription to their offering. Medical industry executives who rely on timely business intelligence now have two smarter alternatives - MedIntelliBase Alerts and MedIntelliBase MarketTracks services. Both cloud and mobile, fully searchable services help biotech, medical device and pharmaceutical companies gain and sustain their competitive advantage. MedIntelliBase gives you customized cloud and mobile intelligence services to satisfy your highly specialized information collection and reporting needs. Highly customized, precisely targeted intelligence on areas of business, finance, regulations, clinical research and medical technology interest are pushed, streamed and accessed as you require. In particular, MedIntelliBase (MIB) MarketTracks are concise Summaries of Clinical Trials and Product Technologies. All Clinical Trial Summaries are indexed by Company, Principal Investigator (PI) and PI Study Site. All Product Technology Summaries are indexed by Company. The Summaries are updated throughout the month published in final form each month with Summary Update Emails sent to you and RSS Breaking News fed to you. For the Subject Area ""Lower Limb ""Critical Limb Ischemia (CLI) Therapeutics - MarketTracks: As of January 2015 the Number of Clinical Trials/Registries included = 45; the Number of Product Technologies included = 25; the Number of Companies included = 22. This Subject Area is growing as its authors discover newly announced trials and emerging product technologies. Key Topics Covered: 1. Arteries 2. Therapeutic Approach 3. Clinical Focus 4. Companies Companies Mentioned - Abbott Vascular Devices - AtheroMed, Inc. - Bard Peripheral Vascular, Inc. / C. R. Bard - BIOTRONIK - Boston Scientific Corporation, Inc. - Cardiovascular Systems, Inc. - Cook, Inc. - Covidien (eV3) - CryoVascular Systems, Inc. (Boston Scientific Corporation) - Edwards Lifesciences - EKOS Corporation - Guidant Corporation (Abbott Vascular Devices/Boston Scientific Corporation) - Intact Vascular, Inc. - Invatec (Medtronic) - Lutonix, Inc. - Medtronic (Bayer / MEDRAD Interventional (Possis Medical, Inc.)) - Medtronic Vascular - Spectranetics Corporation - TriReme Medical - Terumo Medical Corporation - Vascular Solutions, Inc. For more information visit http://www.researchandmarkets.com/research/fg...ntellibase
BSX: 18.41 (+0.10), SPNC: 34.65 (-0.07), MDT: 78.01 (+0.93), CSII: 39.07 (+0.01), EW: 140.87 (+0.39), VASC: 33.30 (+4.06)
MedIntelliBase Lower Limb Advanced Arterial Therapeutics Alerts ("LLA[A] Rx Alerts"
M2 - Mon Apr 20, 9:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48j45j/medintellibase) has announced the addition of the "MedIntelliBase? Lower Limb Advanced Arterial Therapeutics Alerts ("LLA[A] Rx Alerts" " subscription to their offering. MedIntelliBase? Alerts Subject Area - Lower Limb Advanced Arterial Therapeutics Medical industry executives who rely on timely business intelligence now have two smarter alternatives - MedIntelliBase Alerts and MedIntelliBase MarketTracks services. Both cloud and mobile, fully searchable services help biotech, medical device and pharmaceutical companies gain and sustain their competitive advantage. In particular, MedIntelliBase Alerts services instantly gives you the intelligence you need - whenever and wherever you are MedIntelliBase gives you customized cloud and mobile intelligence services to satisfy your highly specialized information collection and reporting needs. Highly customized, precisely targeted intelligence on areas of business, finance, regulations, clinical research and medical technology interest are pushed, streamed and accessed as you require. MedIntelliBase Alerts precisely targets clinical research abstracts and news for you - tracking, filtering, emailing, streaming, pushing via apps and archiving (keyword searchable) critical technology, regulatory and market developments using keywords you specify in your industry segment. This Subject Area is growing as its authors discover news and abstracts about newly emerging product technologies; medical advancements; new competitors; regulatory, legal and commercial activity. Key Topics Covered: 1. Arteries 2. Therapeutic Approach 3. Clinical Focus 4. General PAD Literature 5. Aachen Resonance 6. Abbott Vascular (Guidant Corporation) 7. AngioScore 8. Angioslide 9. Atrium Medical 10. Avinger 11. B. Braun Vascular 12. Bard 13. BIOTRONIK 14. Boston Scientific Corporation 15. Blue Medical 16. Cardionovum 17. Cardiovascular Systems Inc. 18. Cook Medical 19. Cordis 20. Covidien (eV3 / Fox Hollow) 21. Edwards Lifescience 22. EuroCor 23. Hansen Medical 24. Medtronic Vascular (Invatec) 25. NovoStent Corporation 26. Spectranetics 27. Terumo Medical 28. TriReme Medical 29. W. L. Gore For more information visit http://www.researchandmarkets.com/research/48...ntellibase
BSX: 18.41 (+0.10), SPNC: 34.65 (-0.07), MDT: 78.01 (+0.93), CSII: 39.07 (+0.01), HNSN: 0.90 (-0.01)
Healthcare & Energy Companies In Focus: Complementary Research on Boston Scientific, Perrigo, Goldcorp, Johnson & Johnson, Energy XXI Ltd
PR Newswire - Mon Apr 20, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), EXXI: 3.87 (-0.13), PRGO: 201.50 (+8.68), GG: 18.87 (-0.55)
Global Defibrillators Market 2015-2019 - Implantable Cardioverter Defibrillator (Single & Dual Chamber, CRT-D, & S-ICD) and External (Monitor/Defibrillator, AED, & Wearable)
M2 - Mon Apr 20, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4vpdf/defibrillators) has announced the addition of the "Defibrillators Market by Product (Implantable Cardioverter Defibrillator (Single & Dual Chamber, CRT-D, & S-ICD) and External (Monitor/Defibrillator, AED, & Wearable)), by End User (Hospital, Pre-hospital, Public Access, & Home) - Global Forecast to 2019" report to their offering. The global defibrillator market is estimated to grow $12.9 billion by 2019, at a CAGR of 6.9% from 2014 to 2019. Factors such as development of technologically advanced defibrillator, rapid growth in aging population with high risk of target diseases, rising incidences of cardiovascular disease, growing focus of public and private organizations and key market players toward public access defibrillator, and increasing number of training and awareness programs across the globe are propelling the growth of the market. However, lack of awareness about sudden cardiac arrest, issues related to the use of defibrillator devices (external and implantable), and unfavorable healthcare reforms in the U.S. are restraining the growth of this market. In addition to this, the increasing pricing pressure on market players and frequent product recalls are the key challenges faced by market players in the market. On the basis of regions, this market is classified into North America, Europe, Asia-Pacific, and Rest of the World. In 2014, North America is expected to dominate the global defibrillators market. Growth of this region can be attributed to the technological advancements and product innovations, increasing number of public defibrillation programs, rising prevalence of obesity, and rising focus of key players to expand their business in the North American region. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2014 to 2019, due to factors such as rapidly increasing aging population, growing focus of multinational companies on emerging markets, improving and modernizing healthcare infrastructure, and huge burden of cardiovascular disease in this region. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Defibrillators Market, By Product 8 Global Defibrillators Market, By End User 9 Defibrillator Market, By Region 10 Competitive Landscape 11 Company Profiles - Biotronik Se & Co.KG - Boston Scientific Corporation - Cardiac Science Corporation (A Subsidiary of Opto Circuits India Limited) - Heartsine Technologies, Inc. - Medtronic, Inc. - Nihon Kohden Corporation - Philips Healthcare (A Division of Koninklijke Philips N.V.) - Physio-Control, Inc. - ST. Jude Medical, Inc. - Sorin Group - Zoll Medical Corporation (A Subsidiary of Asahi Kasei Corporation) For more information visit http://www.researchandmarkets.com/research/w4...brillators
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43)
Transvaginal Mesh Lawsuit Settlement News Update: Legal-Bay Lawsuit Settlement Funding Announces Judge Order for another Joint Conference Status Meeting to Resolve More than 70K TVM Lawsuits
PR Newswire - Mon Apr 20, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that U.S. District Judge Joseph Goodwin has ordered another joint conference status meeting to hopefully resolve more than 70,000 TVM lawsuits against seven different mesh manufacturers. It is no secret that the TVM multidistrict litigations (MDL) have been dragging on for some time now. With over 70K transvaginal mesh (TVM) lawsuits against seven different mesh manufacturers, the process was expected to take some time. The manufacturers involved in the ordered joint conference status meeting include: American Medical Systems, Bard Avaulta, Boston Scientific, Coloplast, Cook, and Johnson & Johnson's Ethicon. The pretrial order was issued by U.S. District Judge Joseph Goodwin on April 2nd, and the meeting will take place on June 2nd with all of the listed defendant representatives, according to a court document ((1) Bard/TSL & Sofradim MDL 2187; (2) Boston Scientific MDL 2326; (3) Ethicon MDL 2327; (4) Coloplast MDL 2387; (5) Cook MDL 2440).
BSX: 18.41 (+0.10)
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 18.41 (+0.10), ARGS: 8.48 (-0.11), PKI: 51.69 (-0.02)
After Yesterday's Rally of 1.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Apr 17, 4:22PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $17.87 to a high of $18.40. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $18.17 on volume of 17.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 18.41 (+0.10)
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 1.32% Gain
Comtex SmarTrend(R) - Fri Apr 17, 4:21PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $17.87 to a high of $18.40. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $18.17 on volume of 17.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 18.41 (+0.10)
Boston Scientific admits first patient in new study to demonstrate the effect of the Vessix Renal Denervation System in patients with hypertension in the US
M2 - Fri Apr 17, 8:32AM CDT
Medical company Boston Scientific (NYSE:BSX) said on Thursday that it plans to evaluate the performance of the Vessix Renal Denervation System to initiate a study with a novel design to isolate the effects of the therapy in patients with high blood pressure.
BSX: 18.41 (+0.10)
Boston Scientific Enrolls First Patient In New Study Designed To Demonstrate The Effect Of The Vessix(TM) Renal Denervation System
PR Newswire - Thu Apr 16, 3:05PM CDT
Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix(TM) Renal Denervation System, initiating a study with a novel design to isolate the effects of the therapy in patients with high blood pressure, a silent cardiovascular killer affecting millions of people worldwide.
BSX: 18.41 (+0.10)
Boston Scientific Allies to Grow in Chinese Endoscopic Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:40PM CDT
Boston Scientific Corporation (BSX) recently formed a strategic alliance with Frankenman Medical Equipment Company, a maker of surgical staplers with deep local market expertise in China.
BSX: 18.41 (+0.10), SRDX: 26.57 (+0.02), GWPH: 113.04 (-0.05), LMAT: 8.44 (-0.10)
Global Minimal Invasive Device Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnb83x/global_minimal) has announced the addition of the "Global Minimal Invasive Device Market Outlook 2020" report to their offering. The market for minimally invasive medical devices has reached US$ 15 Billion in 2014. In the latest edition Global Minimally Invasive Device Market Outlook 2020, analysts have studied the dynamics of minimally invasive medical industry comprehensively. The report provides information on the current scenario, market segmentation on the basis of surgical devices and geography, and future estimations till 2020. The report also covers major factors propelling the growth of the industry, the regulatory framework, challenges holding back the industry, latest trends and developments, and mergers & acquisitions that have taken place in the past two years. The industry is facing cut-throat competition with the presence of existing as well as emerging players. The market is dominated by the US based medical robot manufacturer, Intuitive Surgical, with other notable players being GE Healthcare and Siemens Healthcare. Finally, to understand transparency of the existing competition, a separate section is devoted to the Porter's five forces model. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the minimally invasive market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. A Brief Overview 4. Drivers 5. Challenges 6. Market Overview 7. Regulatory Landscape 8. Market Trends and Developments 9. Mergers & Acquisitions 10. Competitive Landscape 11. Porter's Five Forces Analysis Companies Mentioned - Intuitive Surgical - Medtronic Inc - Stryker Corporation - Boston Scientific - GE Healthcare - Covidien - Siemens Healthcare - Philip Healthcare - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/tn...al_minimal
ISRG: 516.93 (-29.80), BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), MDT: 78.01 (+0.93), SYK: 96.45 (+1.74)
Boston Scientific Has Returned 38.9% Since SmarTrend Recommendation (BSX)
Comtex SmarTrend(R) - Tue Apr 14, 4:50PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on October 24th, 2014 at $12.89. In approximately 6 months, Boston Scientific has returned 38.92% as of today's recent price of $17.90.
BSX: 18.41 (+0.10)
Boston Scientific (BSX) Stock Gains Today on Agreement Expanding Reach in China
at The Street - Tue Apr 14, 2:57PM CDT
Boston Scientific (BSX) announced an agreement with Frankenman Medical Equipment that expands its footprint in the Chinese medical device market.
BSX: 18.41 (+0.10)
Global Oncology Ablation Market Outlook 2014-2020
M2 - Tue Apr 14, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksr667/global_oncology) has announced the addition of the "Global Oncology Ablation Market Outlook: 2014-2020" report to their offering. The research report titled Global Oncology Ablation Market Outlook: 2014-2020 provides in-depth analysis of oncology ablation market in four major geographies. The report also emphasizes on the current trends in oncology ablation, market size, market share, recent developments, and forecasts till 2020. Oncology Ablation is the minimal invasive treatment that is used to destroy or inactive the cancer cells and tumors. The market for oncology ablation is on the rise due to increasing number of cancer diagnosis and high acceptance rate among the cancer community across the world. Over the traditional treatment, oncology ablation has many advantages as it is minimal invasive treatment that makes the recovery easy and quick; also it provides relief to patients who are reluctant to go for a surgery. Image guided ablation treatments promises the accuracy in destruction of tumor cells without damaging the uninfected cells. The study offers a comprehensive analysis of oncology ablation market with respect to various technologies and type of cancer. The technologies analyzed in this report are radiofrequency ablation, microwave ablation, cryoablation, ethanol ablation, irreversible electroporesis (IRE), light (laser ablation), and ultrasound ablation; whereas, the cancer types analyzed in the report are lung cancer, liver cancer, breast cancer, kidney cancer, colorectal cancer and prostate cancer. Comprehensive geographical analysis of the oncology ablation is provided by segmenting the global market on the basis of major continents, namely, North America, Europe, Asia Pacific, and RoW (Rest of the World) which are further analyzed at a country level. The report offers meticulous analysis of market dynamics, burning issues, and technological landscape of the global oncology ablation market. The report provides the competitive landscape of the major players in this market with detailed analysis of their product portfolio, financials, and recent developments. Key Topics Covered: 1 Introduction to Global Oncology Ablation Market 2 Executive Summary 3 Market Insights 4 Global Oncology Ablation Market, By Technology 5 Global Oncology Ablation Market, By Type Of Cancer 6 Oncology Ablation Market, By Geography 7 Competitive Landscape- Global Oncology Ablation Market 8 Company Profiles - APRO KOREA - Accuray Inc. - AngioDynamics - BSD Medical - Boston Scientific - Celon AG (Olympus) - Covidien - Elekta AB - Galil Medical - HealthTronics Inc. - MedWaves Incorporated - Misonix Inc. - NeuWave Medical - RF Medical Co. Ltd - STARMed Co. Ltd - SonaCare Medical - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/ks...l_oncology
BSX: 18.41 (+0.10), VAR: 95.97 (+0.52), MSON: 13.30 (+0.14), BSDM: 0.62 (+0.13), ARAY: 9.00 (unch)
Boston Scientific Has Returned 42.5% Since SmarTrend Recommendation (BSX)
Comtex SmarTrend(R) - Wed Apr 22, 9:18AM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on October 24th, 2014 at $12.89. In approximately 6 months, Boston Scientific has returned 42.49% as of today's recent price of $18.36.
BSX: 18.41 (+0.10)
Boston Scientific (BSX) Breaks Through Resistance at $18.38
Comtex SmarTrend(R) - Wed Apr 22, 9:10AM CDT
Shares of Boston Scientific (NYSE:BSX) have bullishly opened above the pivot of $18.25 today and have reached the first resistance level of $18.38. Analysts will be watching for a cross of the next upside pivot targets of $18.44 and $18.63.
BSX: 18.41 (+0.10)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), UPI: 1.22 (-0.03), CYBX: 63.59 (+0.27)
C. R. Bard (BCR) Q1 Earnings: Lutonix DCB Holds the Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:20PM CDT
C.R. Bard Inc. (BAX) is set to report first-quarter 2015 earnings results on Apr 23.
BSX: 18.41 (+0.10), BIIB: 423.57 (+1.46), BCR: 175.09 (+0.24), ATHN: 120.16 (-1.35)
Long-Term Data Underscore Safety And Efficacy Of The Boston Scientific S-ICD(TM) System
PR Newswire - Mon Apr 20, 3:01PM CDT
Today the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX) S-ICD System(TM) (subcutaneous implantable defibrillator) for patients at risk of sudden cardiac arrest.
BSX: 18.41 (+0.10)
MedIntelliBase Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks"
M2 - Mon Apr 20, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fgkmfx/medintellibase) has announced the addition of the "MedIntelliBase? Lower Limb Critical Limb Ischemia Therapeutics MarketTracksTM ("CLI-LL MarketTracks"
" subscription to their offering. Medical industry executives who rely on timely business intelligence now have two smarter alternatives - MedIntelliBase Alerts and MedIntelliBase MarketTracks services. Both cloud and mobile, fully searchable services help biotech, medical device and pharmaceutical companies gain and sustain their competitive advantage. MedIntelliBase gives you customized cloud and mobile intelligence services to satisfy your highly specialized information collection and reporting needs. Highly customized, precisely targeted intelligence on areas of business, finance, regulations, clinical research and medical technology interest are pushed, streamed and accessed as you require. In particular, MedIntelliBase (MIB) MarketTracks are concise Summaries of Clinical Trials and Product Technologies. All Clinical Trial Summaries are indexed by Company, Principal Investigator (PI) and PI Study Site. All Product Technology Summaries are indexed by Company. The Summaries are updated throughout the month published in final form each month with Summary Update Emails sent to you and RSS Breaking News fed to you. For the Subject Area ""Lower Limb ""Critical Limb Ischemia (CLI) Therapeutics - MarketTracks: As of January 2015 the Number of Clinical Trials/Registries included = 45; the Number of Product Technologies included = 25; the Number of Companies included = 22. This Subject Area is growing as its authors discover newly announced trials and emerging product technologies. Key Topics Covered: 1. Arteries 2. Therapeutic Approach 3. Clinical Focus 4. Companies Companies Mentioned - Abbott Vascular Devices - AtheroMed, Inc. - Bard Peripheral Vascular, Inc. / C. R. Bard - BIOTRONIK - Boston Scientific Corporation, Inc. - Cardiovascular Systems, Inc. - Cook, Inc. - Covidien (eV3) - CryoVascular Systems, Inc. (Boston Scientific Corporation) - Edwards Lifesciences - EKOS Corporation - Guidant Corporation (Abbott Vascular Devices/Boston Scientific Corporation) - Intact Vascular, Inc. - Invatec (Medtronic) - Lutonix, Inc. - Medtronic (Bayer / MEDRAD Interventional (Possis Medical, Inc.)) - Medtronic Vascular - Spectranetics Corporation - TriReme Medical - Terumo Medical Corporation - Vascular Solutions, Inc. For more information visit http://www.researchandmarkets.com/research/fg...ntellibase BSX: 18.41 (+0.10), SPNC: 34.65 (-0.07), MDT: 78.01 (+0.93), CSII: 39.07 (+0.01), EW: 140.87 (+0.39), VASC: 33.30 (+4.06)
MedIntelliBase Lower Limb Advanced Arterial Therapeutics Alerts ("LLA[A] Rx Alerts"
M2 - Mon Apr 20, 9:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48j45j/medintellibase) has announced the addition of the "MedIntelliBase? Lower Limb Advanced Arterial Therapeutics Alerts ("LLA[A] Rx Alerts"
" subscription to their offering. MedIntelliBase? Alerts Subject Area - Lower Limb Advanced Arterial Therapeutics Medical industry executives who rely on timely business intelligence now have two smarter alternatives - MedIntelliBase Alerts and MedIntelliBase MarketTracks services. Both cloud and mobile, fully searchable services help biotech, medical device and pharmaceutical companies gain and sustain their competitive advantage. In particular, MedIntelliBase Alerts services instantly gives you the intelligence you need - whenever and wherever you are MedIntelliBase gives you customized cloud and mobile intelligence services to satisfy your highly specialized information collection and reporting needs. Highly customized, precisely targeted intelligence on areas of business, finance, regulations, clinical research and medical technology interest are pushed, streamed and accessed as you require. MedIntelliBase Alerts precisely targets clinical research abstracts and news for you - tracking, filtering, emailing, streaming, pushing via apps and archiving (keyword searchable) critical technology, regulatory and market developments using keywords you specify in your industry segment. This Subject Area is growing as its authors discover news and abstracts about newly emerging product technologies; medical advancements; new competitors; regulatory, legal and commercial activity. Key Topics Covered: 1. Arteries 2. Therapeutic Approach 3. Clinical Focus 4. General PAD Literature 5. Aachen Resonance 6. Abbott Vascular (Guidant Corporation) 7. AngioScore 8. Angioslide 9. Atrium Medical 10. Avinger 11. B. Braun Vascular 12. Bard 13. BIOTRONIK 14. Boston Scientific Corporation 15. Blue Medical 16. Cardionovum 17. Cardiovascular Systems Inc. 18. Cook Medical 19. Cordis 20. Covidien (eV3 / Fox Hollow) 21. Edwards Lifescience 22. EuroCor 23. Hansen Medical 24. Medtronic Vascular (Invatec) 25. NovoStent Corporation 26. Spectranetics 27. Terumo Medical 28. TriReme Medical 29. W. L. Gore For more information visit http://www.researchandmarkets.com/research/48...ntellibase BSX: 18.41 (+0.10), SPNC: 34.65 (-0.07), MDT: 78.01 (+0.93), CSII: 39.07 (+0.01), HNSN: 0.90 (-0.01)
Healthcare & Energy Companies In Focus: Complementary Research on Boston Scientific, Perrigo, Goldcorp, Johnson & Johnson, Energy XXI Ltd
PR Newswire - Mon Apr 20, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), EXXI: 3.87 (-0.13), PRGO: 201.50 (+8.68), GG: 18.87 (-0.55)
Global Defibrillators Market 2015-2019 - Implantable Cardioverter Defibrillator (Single & Dual Chamber, CRT-D, & S-ICD) and External (Monitor/Defibrillator, AED, & Wearable)
M2 - Mon Apr 20, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4vpdf/defibrillators) has announced the addition of the "Defibrillators Market by Product (Implantable Cardioverter Defibrillator (Single & Dual Chamber, CRT-D, & S-ICD) and External (Monitor/Defibrillator, AED, & Wearable)), by End User (Hospital, Pre-hospital, Public Access, & Home) - Global Forecast to 2019" report to their offering. The global defibrillator market is estimated to grow $12.9 billion by 2019, at a CAGR of 6.9% from 2014 to 2019. Factors such as development of technologically advanced defibrillator, rapid growth in aging population with high risk of target diseases, rising incidences of cardiovascular disease, growing focus of public and private organizations and key market players toward public access defibrillator, and increasing number of training and awareness programs across the globe are propelling the growth of the market. However, lack of awareness about sudden cardiac arrest, issues related to the use of defibrillator devices (external and implantable), and unfavorable healthcare reforms in the U.S. are restraining the growth of this market. In addition to this, the increasing pricing pressure on market players and frequent product recalls are the key challenges faced by market players in the market. On the basis of regions, this market is classified into North America, Europe, Asia-Pacific, and Rest of the World. In 2014, North America is expected to dominate the global defibrillators market. Growth of this region can be attributed to the technological advancements and product innovations, increasing number of public defibrillation programs, rising prevalence of obesity, and rising focus of key players to expand their business in the North American region. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2014 to 2019, due to factors such as rapidly increasing aging population, growing focus of multinational companies on emerging markets, improving and modernizing healthcare infrastructure, and huge burden of cardiovascular disease in this region. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Defibrillators Market, By Product 8 Global Defibrillators Market, By End User 9 Defibrillator Market, By Region 10 Competitive Landscape 11 Company Profiles - Biotronik Se & Co.KG - Boston Scientific Corporation - Cardiac Science Corporation (A Subsidiary of Opto Circuits India Limited) - Heartsine Technologies, Inc. - Medtronic, Inc. - Nihon Kohden Corporation - Philips Healthcare (A Division of Koninklijke Philips N.V.) - Physio-Control, Inc. - ST. Jude Medical, Inc. - Sorin Group - Zoll Medical Corporation (A Subsidiary of Asahi Kasei Corporation) For more information visit http://www.researchandmarkets.com/research/w4...brillators
BSX: 18.41 (+0.10), MDT: 78.01 (+0.93), STJ: 73.55 (+4.43)
Transvaginal Mesh Lawsuit Settlement News Update: Legal-Bay Lawsuit Settlement Funding Announces Judge Order for another Joint Conference Status Meeting to Resolve More than 70K TVM Lawsuits
PR Newswire - Mon Apr 20, 4:00AM CDT
Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that U.S. District Judge Joseph Goodwin has ordered another joint conference status meeting to hopefully resolve more than 70,000 TVM lawsuits against seven different mesh manufacturers. It is no secret that the TVM multidistrict litigations (MDL) have been dragging on for some time now. With over 70K transvaginal mesh (TVM) lawsuits against seven different mesh manufacturers, the process was expected to take some time. The manufacturers involved in the ordered joint conference status meeting include: American Medical Systems, Bard Avaulta, Boston Scientific, Coloplast, Cook, and Johnson & Johnson's Ethicon. The pretrial order was issued by U.S. District Judge Joseph Goodwin on April 2nd, and the meeting will take place on June 2nd with all of the listed defendant representatives, according to a court document ((1) Bard/TSL & Sofradim MDL 2187; (2) Boston Scientific MDL 2326; (3) Ethicon MDL 2327; (4) Coloplast MDL 2387; (5) Cook MDL 2440).
BSX: 18.41 (+0.10)
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 18.41 (+0.10), ARGS: 8.48 (-0.11), PKI: 51.69 (-0.02)
After Yesterday's Rally of 1.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Apr 17, 4:22PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $17.87 to a high of $18.40. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $18.17 on volume of 17.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 18.41 (+0.10)
SmarTrend Watching for Potential Pullback in Shares of Boston Scientific After 1.32% Gain
Comtex SmarTrend(R) - Fri Apr 17, 4:21PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $17.87 to a high of $18.40. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $18.17 on volume of 17.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 18.41 (+0.10)
Boston Scientific admits first patient in new study to demonstrate the effect of the Vessix Renal Denervation System in patients with hypertension in the US
M2 - Fri Apr 17, 8:32AM CDT
Medical company Boston Scientific (NYSE:BSX) said on Thursday that it plans to evaluate the performance of the Vessix Renal Denervation System to initiate a study with a novel design to isolate the effects of the therapy in patients with high blood pressure.
BSX: 18.41 (+0.10)
Boston Scientific Enrolls First Patient In New Study Designed To Demonstrate The Effect Of The Vessix(TM) Renal Denervation System
PR Newswire - Thu Apr 16, 3:05PM CDT
Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix(TM) Renal Denervation System, initiating a study with a novel design to isolate the effects of the therapy in patients with high blood pressure, a silent cardiovascular killer affecting millions of people worldwide.
BSX: 18.41 (+0.10)
Boston Scientific Allies to Grow in Chinese Endoscopic Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:40PM CDT
Boston Scientific Corporation (BSX) recently formed a strategic alliance with Frankenman Medical Equipment Company, a maker of surgical staplers with deep local market expertise in China.
BSX: 18.41 (+0.10), SRDX: 26.57 (+0.02), GWPH: 113.04 (-0.05), LMAT: 8.44 (-0.10)
Global Minimal Invasive Device Market Outlook 2020
M2 - Thu Apr 16, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnb83x/global_minimal) has announced the addition of the "Global Minimal Invasive Device Market Outlook 2020" report to their offering. The market for minimally invasive medical devices has reached US$ 15 Billion in 2014. In the latest edition Global Minimally Invasive Device Market Outlook 2020, analysts have studied the dynamics of minimally invasive medical industry comprehensively. The report provides information on the current scenario, market segmentation on the basis of surgical devices and geography, and future estimations till 2020. The report also covers major factors propelling the growth of the industry, the regulatory framework, challenges holding back the industry, latest trends and developments, and mergers & acquisitions that have taken place in the past two years. The industry is facing cut-throat competition with the presence of existing as well as emerging players. The market is dominated by the US based medical robot manufacturer, Intuitive Surgical, with other notable players being GE Healthcare and Siemens Healthcare. Finally, to understand transparency of the existing competition, a separate section is devoted to the Porter's five forces model. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the minimally invasive market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. A Brief Overview 4. Drivers 5. Challenges 6. Market Overview 7. Regulatory Landscape 8. Market Trends and Developments 9. Mergers & Acquisitions 10. Competitive Landscape 11. Porter's Five Forces Analysis Companies Mentioned - Intuitive Surgical - Medtronic Inc - Stryker Corporation - Boston Scientific - GE Healthcare - Covidien - Siemens Healthcare - Philip Healthcare - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/tn...al_minimal
ISRG: 516.93 (-29.80), BSX: 18.41 (+0.10), JNJ: 100.43 (+0.13), MDT: 78.01 (+0.93), SYK: 96.45 (+1.74)
Boston Scientific Has Returned 38.9% Since SmarTrend Recommendation (BSX)
Comtex SmarTrend(R) - Tue Apr 14, 4:50PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on October 24th, 2014 at $12.89. In approximately 6 months, Boston Scientific has returned 38.92% as of today's recent price of $17.90.
BSX: 18.41 (+0.10)
Boston Scientific (BSX) Stock Gains Today on Agreement Expanding Reach in China
at The Street - Tue Apr 14, 2:57PM CDT
Boston Scientific (BSX) announced an agreement with Frankenman Medical Equipment that expands its footprint in the Chinese medical device market.
BSX: 18.41 (+0.10)
Global Oncology Ablation Market Outlook 2014-2020
M2 - Tue Apr 14, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksr667/global_oncology) has announced the addition of the "Global Oncology Ablation Market Outlook: 2014-2020" report to their offering. The research report titled Global Oncology Ablation Market Outlook: 2014-2020 provides in-depth analysis of oncology ablation market in four major geographies. The report also emphasizes on the current trends in oncology ablation, market size, market share, recent developments, and forecasts till 2020. Oncology Ablation is the minimal invasive treatment that is used to destroy or inactive the cancer cells and tumors. The market for oncology ablation is on the rise due to increasing number of cancer diagnosis and high acceptance rate among the cancer community across the world. Over the traditional treatment, oncology ablation has many advantages as it is minimal invasive treatment that makes the recovery easy and quick; also it provides relief to patients who are reluctant to go for a surgery. Image guided ablation treatments promises the accuracy in destruction of tumor cells without damaging the uninfected cells. The study offers a comprehensive analysis of oncology ablation market with respect to various technologies and type of cancer. The technologies analyzed in this report are radiofrequency ablation, microwave ablation, cryoablation, ethanol ablation, irreversible electroporesis (IRE), light (laser ablation), and ultrasound ablation; whereas, the cancer types analyzed in the report are lung cancer, liver cancer, breast cancer, kidney cancer, colorectal cancer and prostate cancer. Comprehensive geographical analysis of the oncology ablation is provided by segmenting the global market on the basis of major continents, namely, North America, Europe, Asia Pacific, and RoW (Rest of the World) which are further analyzed at a country level. The report offers meticulous analysis of market dynamics, burning issues, and technological landscape of the global oncology ablation market. The report provides the competitive landscape of the major players in this market with detailed analysis of their product portfolio, financials, and recent developments. Key Topics Covered: 1 Introduction to Global Oncology Ablation Market 2 Executive Summary 3 Market Insights 4 Global Oncology Ablation Market, By Technology 5 Global Oncology Ablation Market, By Type Of Cancer 6 Oncology Ablation Market, By Geography 7 Competitive Landscape- Global Oncology Ablation Market 8 Company Profiles - APRO KOREA - Accuray Inc. - AngioDynamics - BSD Medical - Boston Scientific - Celon AG (Olympus) - Covidien - Elekta AB - Galil Medical - HealthTronics Inc. - MedWaves Incorporated - Misonix Inc. - NeuWave Medical - RF Medical Co. Ltd - STARMed Co. Ltd - SonaCare Medical - Varian Medical Systems For more information visit http://www.researchandmarkets.com/research/ks...l_oncology
BSX: 18.41 (+0.10), VAR: 95.97 (+0.52), MSON: 13.30 (+0.14), BSDM: 0.62 (+0.13), ARAY: 9.00 (unch)
